ebomi
Colour theme
Sign in
Insider · CIK 0001384859

Kolchinsky Peter

CIK 0001384859 Name as filed on the most recent filing

Filed as Kolchinsky Peter (248)

1,080 transaction lines · from 248 filings · filed 2006-12-29 to 2026-08-14 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised. The 40 most recent are shown; the catalog may hold more for this insider.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

11 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-05-12 S, Open-market sale Werewolf Therapeutics, Inc.HOWL 4,300, disposed Open Form 4 filing 0001231919-26-000485
2026-05-11 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 74,999,992, acquired Open Form 4 filing 0001231919-26-000491
2026-05-11 P, Open-market purchase Hemab Therapeutics Holdings, Inc.COAG 2 lines 989,226, acquired Open Form 4 filing 0001231919-26-000475
2026-05-11 S, Open-market sale Werewolf Therapeutics, Inc.HOWL 2 lines 58,618, disposed Open Form 4 filing 0001231919-26-000485
2026-05-08 P, Open-market purchase Hemab Therapeutics Holdings, Inc.COAG 37,045, acquired Open Form 4 filing 0001231919-26-000475
2026-05-08 S, Open-market sale Werewolf Therapeutics, Inc.HOWL 2 lines 267,333, disposed Open Form 4 filing 0001231919-26-000485
2026-05-07 P, Open-market purchase Hemab Therapeutics Holdings, Inc.COAG 2 lines 242,323, acquired Open Form 4 filing 0001231919-26-000475
2026-05-06 P, Open-market purchase Hemab Therapeutics Holdings, Inc.COAG 2 lines 1,673,399, acquired Open Form 4 filing 0001231919-26-000457
2026-05-05 P, Open-market purchase Hemab Therapeutics Holdings, Inc.COAG 2 lines 2,399,546, acquired Open Form 4 filing 0001231919-26-000457
2026-05-04 P, Open-market purchase Hemab Therapeutics Holdings, Inc.COAG 2 lines 48,150,000, acquired Open Form 4 filing 0001231919-26-000457
2026-04-22 S, Open-market sale Vor Biopharma Inc.VOR 2,604,416, disposed Open Form 4 filing 0001231919-26-000409
2026-04-20 S, Open-market sale Vor Biopharma Inc.VOR 2,711,857, disposed Open Form 4 filing 0001231919-26-000385
2026-04-17 S, Open-market sale Vor Biopharma Inc.VOR 7,462,931, disposed Open Form 4 filing 0001231919-26-000385
2026-04-15 S, Open-market sale Vor Biopharma Inc.VOR 858,840, disposed Open Form 4 filing 0001231919-26-000355
2026-04-14 S, Open-market sale Vor Biopharma Inc.VOR 2,455,148, disposed Open Form 4 filing 0001231919-26-000355
2026-04-13 S, Open-market sale Vor Biopharma Inc.VOR 8,569,352, disposed Open Form 4 filing 0001231919-26-000355
2026-04-10 S, Open-market sale Vor Biopharma Inc.VOR 13,041, disposed Open Form 4 filing 0001231919-26-000333
2026-04-09 S, Open-market sale Vor Biopharma Inc.VOR 2,242,985, disposed Open Form 4 filing 0001231919-26-000333
2026-04-08 S, Open-market sale Vor Biopharma Inc.VOR 2 lines 7,977,786, disposed Open Form 4 filing 0001231919-26-000333
2026-04-06 S, Open-market sale Vor Biopharma Inc.VOR 3 lines 9,777,898, disposed Open Form 4 filing 0001231919-26-000320
2026-04-02 S, Open-market sale Vor Biopharma Inc.VOR 2 lines 4,741,066, disposed Open Form 4 filing 0001231919-26-000320
2026-03-30 P, Open-market purchase Mineralys Therapeutics, Inc.MLYS 1,408,528, acquired Open Form 4 filing 0001231919-26-000300
2026-03-30 P, Open-market purchase Wave Life Sciences Ltd.WVE 6,312,092, acquired Open Form 4 filing 0001231919-26-000297
2026-03-27 P, Open-market purchase Mineralys Therapeutics, Inc.MLYS 7,354,269, acquired Open Form 4 filing 0001231919-26-000300
2026-03-27 P, Open-market purchase Wave Life Sciences Ltd.WVE 16,046,856, acquired Open Form 4 filing 0001231919-26-000297
2026-03-26 P, Open-market purchase Wave Life Sciences Ltd.WVE 2 lines 32,265,431, acquired Open Form 4 filing 0001231919-26-000297
2026-02-26 P, Open-market purchase Bicara Therapeutics Inc.BCAX 4,800,000, acquired Open Form 4 filing 0001231919-26-000231
2026-02-20 P, Open-market purchase Adicet Bio, Inc.ACET 543,440, acquired Open Form 4 filing 0001231919-26-000337
2026-02-19 P, Open-market purchase Adicet Bio, Inc.ACET 535,472, acquired Open Form 4 filing 0001231919-26-000337
2026-02-18 P, Open-market purchase Adicet Bio, Inc.ACET 525,022, acquired Open Form 4 filing 0001231919-26-000337
2026-02-09 P, Open-market purchase SpyGlass Pharma, Inc.SGP 2 lines 59,040,000, acquired Open Form 4 filing 0001231919-26-000135
2026-01-05 P, Open-market purchase Climb Bio, Inc.CLYM 24,889, acquired Open Form 4 filing 0001231919-26-000018
2025-12-12 P, Open-market purchase Climb Bio, Inc.CLYM 290,181, acquired Open Form 4 filing 0001231919-25-000616
2025-12-11 P, Open-market purchase Climb Bio, Inc.CLYM 464,556, acquired Open Form 4 filing 0001231919-25-000616
2025-12-08 S, Open-market sale Fulcrum Therapeutics, Inc.FULC 3 lines 58,377,021, disposed Open Form 4 filing 0001231919-25-000596

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 2
  • Open-market sale 9
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Kolchinsky Peter, insider transactions. Retrieved 2026-08-23 from https://ebomi.com/insider/0001384859

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.